SHANGHAI, July 10, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has again been named as a constituent company of the FTSE4Good Index Series. This marks the fourth consecutive year the company has been included in the Index for its outstanding sustainability performance.
WuXi Biologics Named Constituent of the FTSE4Good Index Series
Launched in 2001 by the global index and data provider FTSE Russell, which is wholly owned by the London Stock Exchange Group, the FTSE4Good Index Series is designed to measure the performance of companies demonstrating good sustainability practices. Inclusion in the FTSE4Good Index Series is based on independent analysis of data from over 8,000 securities in 47 developed and emerging countries. Over the past years, WuXi Biologics has realized substantial improvements in its overall FTSE Russell ESG score, as well as its theme scores. The company's ESG score in 2024 achieved the top 7% in its industry.
Dr. Chris Chen, WuXi Biologics CEO and Chairman of the ESG Committee, commented, "We are very proud to be acknowledged again by FTSE Russell as a constituent of the FTSE4Good Index Series. It underscores our firm commitment to sustainability, demonstrating the success of our comprehensive ESG strategy and our effective implementation of ESG approaches. Moving forward, we will continue to regard sustainability as the cornerstone of business growth, delivering consistently strong performance for the common good of the global community."
In line with the United Nations Sustainable Development Goals, WuXi Biologics has been making steady progress in pursuing sustainable development, which has been recognized by major ESG rating agencies. In the past year, the company was added to the S&P Dow Jones Sustainability World Index and Emerging Markets Index; granted a "AAA" rating from MSCI ESG Ratings; awarded the distinguished Platinum Medal by EcoVadis; recognized as an Industry and Regional Top-Rated Company by Sustainalytics; named to the CDP Water Security "A list"; and awarded an "A-" CDP Climate Change score.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2023, WuXi Biologics is supporting 698 integrated client projects, including 24 in commercial manufacturing.
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to be an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: .
"ESG コミットティーの議長である薬明生物の CEO である Chris Chen 博士は、「FTSE Russell から再び FTSE4Good インデックスシリーズの構成企業として認められたことを誇りに思います。これは、持続可能性に対する我々の強いコミットメントを証明しており、包括的な ESG 戦略と効果的な ESG アプローチの実施の成功を示しています。今後も、持続可能性をビジネス成長の基盤として捉え、グローバルコミュニティの共通の利益のために、着実なパフォーマンスを提供し続けます」と述べています。
国際連合持続可能な開発目標に合わせ、薬明生物は持続可能な開発を追求し、主要な ESG 評価機関から評価を受けています。過去 1 年間、同社は S&P ダウ・ジョーンズ・サステナビリティ世界指数や新興市場指数に追加され、MSCI ESG 評価で「AAA」評価を受け、EcoVadis から著名な Platinum Medal を授与され、Sustainalytics による業種および地域別のトップ評価企業に認定され、CDP Water Security「A list」に選出され、CDP Climate Change スコアで「A-」を獲得しました。
薬明生物について
薬明生物 (証券コード: 2269.HK) は、概念から商業化までの生物製剤の発見、開発、製造を実現するエンドツーエンドのソリューションを提供する、世界をリードする CRDMO (Contract Research, Development and Manufacturing Organization) です。
オーストラリアでは、moomooの投資商品及びサービスはMoomoo Securities Australia Limitedによって提供され、オーストラリア証券投資委員会（ASIC）の管理を受けております（AFSL No. 224663）。「金融サービスガイド」、「利用規約」、「プライバシーポリシー」などの詳細は、Moomoo Securities Australia Limitedのウェブサイトhttps://www.moomoo.com/auでご確認いただけます。
オーストラリアでは、moomooの投資商品及びサービスはMoomoo Securities Australia Limitedによって提供され、オーストラリア証券投資委員会（ASIC）の管理を受けております（AFSL No. 224663）。「金融サービスガイド」、「利用規約」、「プライバシーポリシー」などの詳細は、Moomoo Securities Australia Limitedのウェブサイトhttps://www.moomoo.com/auでご確認いただけます。
